DaVita Inc. (DVA)

The company now

DaVita reported its results for the quarter ended June 30, 2026 on August 4 7. Revenue was $3,554 million, up from $3,380 million in the same quarter a year earlier 2. Net income attributable to the company was $265 million, against $199 million a year earlier 2.

Treatments per day rose against the same quarter a year before 2. The company says patient numbers came in better than it expected, mainly because fewer patients died than it had planned for 2.

Average revenue per treatment, the payment for one dialysis session, was $416.71 in the first six months of the year against $402.38 a year earlier 2. The company credits Medicare rate increases, partly offset by a weaker mix of insurers 2.

One open question is the mix of insurers 2. The company says the end of enhanced premium tax credits at the end of 2025 hurt enrollment in exchange plans and its commercial mix 2. Commercial plans pay more than government programs, so the mix matters to revenue per treatment 1.

As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.